India's first public sector proton beam therapy unit to come up in Assam; state signs MoU with Belgian firm

Assam has signed an MoU with Belgium-based Ion Beam Applications (IBA) to set up India's first public-sector proton beam therapy centre in Guwahati at a cost of Rs 600 crore. The facility will offer advanced cancer treatment, particularly for children, and is expected to take at least three years to become operational.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8QGNRKm
via IFTTT

Read More

Cancer drug prices fell in 2019 too, but mark-ups of up to 700% are back

The government's latest cancer drug price cuts may offer patients some relief, but the impact could be short-lived. An analysis of medicines covered in the 2019 exercise found that mark-ups had risen to as much as 700% by 2026, raising questions about whether one-time price cuts can keep cancer treatment affordable.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lV5JvIn
via IFTTT

Read More

Sun Pharma books Rs 346 crore Organon deal costs in Q2; profit falls 36%

Sun Pharmaceutical Industries experienced a significant decline in net profit during the September quarter of FY27. The company incurred acquisition-related costs of Rs 346.16 crore while preparing for the Organon acquisition. Revenue from operations increased by 11.9% compared to the same quarter last year. An important settlement of Rs 922.67 crore was reached concerning a litigation in the US. The transaction with Organon is expected to close in Q4 FY27.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lVIyPuW
via IFTTT

Read More

Omron Healthcare eyes Chennai as global manufacturing hub, targets 3 million BP monitors by 2028

Omron Healthcare has commenced full-scale production at its new facility near Chennai for blood pressure monitors. The company aims to produce three million monitors annually by 2028 for the Indian market. Initially, all produced devices will serve local consumers to address cardiovascular health challenges. Omron is also working towards increasing domestic sourcing of components to support local manufacturing initiatives.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2JSVslj
via IFTTT

Read More

NPPA list brings little relief: No price cut for 25% cancer drugs

Nearly one in four cancer drug packs in the NPPA’s revised price list will see no reduction in MRP, even as the overall average cut across 643 packs is 38.22%. Several high-cost patented medicines remain unchanged, prompting patient advocates to question how much relief the trade-margin cap will actually deliver when the new prices take effect on November 9.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hqpvYDO
via IFTTT

Read More

India's pharma exports rise 4.9% to USD 16.14 bn in H1; shipments to Europe up nearly 10%: Pharmexcil

India's pharmaceutical exports increased nearly 5 percent, reaching USD 16.13 billion in the first half of the fiscal year. Growth was driven by strong demand from Europe, ASEAN, and Latin America. Shipments included drug formulations, biologicals, bulk drugs, and surgical products. Exports to key regions, particularly Europe and ASEAN, rose significantly during this period. Industry leaders emphasized the need for India to enhance its pharmaceutical innovation and manufacturing capabilities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1prYPNv
via IFTTT

Read More

Piramal Pharma cutting China exposure to manage supply-chain resilience, says Nandini Piramal

In a strategic move to enhance risk management, Piramal Pharma has drastically cut its reliance on Chinese raw materials to under 10%. The company is actively diversifying its supply chains to provide greater flexibility against geopolitical challenges while broadening its manufacturing footprint to locations like India, the UK, and the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LhrKOSZ
via IFTTT

Read More

SC pulls up Centre over soaring medicine costs

The Supreme Court expressed concern over the government's role in allowing steep medicine prices to persist. Justices Vikram Nath and Sandeep Mehta questioned the justification for significant price discrepancies faced by patients. The court highlighted a lack of accountability regarding how drug manufacturers benefit from inflated prices. Government representatives stated that regulatory measures should not encompass the entire drug pricing ecosystem.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WKD2ST4
via IFTTT

Read More

Cipla sets sights on first-wave gains from rollout of Keytruda Biosimilar

Cipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for this drug is expected to expire around 2029, allowing for potential market entry. Cipla anticipates capturing a significant share of this lucrative market segment after the launch. Additionally, the company reported a 35% decline in consolidated net profit in the September quarter.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/q27gIB0
via IFTTT

Read More

Healthware partners Fujifilm to expand use of precision surgical imaging solutions

Healthware has entered a partnership with Fujifilm to expand the use of intra-operative ultrasound systems across India. This collaboration aims to meet the critical clinical needs in complex surgeries. Real-time surgical ultrasound will be made available in more operating rooms, enhancing the speed of surgical procedures. The partnership combines technological innovation with clinical expertise for better patient outcomes. Healthware's national service and support network will facilitate this advancement in healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/R63ECuB
via IFTTT

Read More

Cipla expects US business to draw support from upcoming product pipeline

Cipla reported a significant decline in its consolidated net profit for the second quarter of FY27. The company's North American revenue fell by 19% due to increased competition impacting sales of generic Revlimid. However, Cipla anticipates that its upcoming product pipeline will support performance in North America. In India, domestic revenue rose, providing some resilience amidst challenges in the US market.

from Healthcare/Biotech-Industry-Economic Times https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/cipla-expects-us-business-to-draw-support-from-upcoming-product-pipeline/articleshow/135229843.cms
via IFTTT

Read More

Sakar Healthcare posts Rs 11 cr profit in Q2

The company said the second quarter growth was supported by new oncology approvals, strong demand across geographies, a better oncology mix, operating leverage, and disciplined cost management.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/atrA53o
via IFTTT

Read More

Mankind Pharma shares key business developments from Q2 & H1 of FY27

The company outperformed the market by 1.1 times in both chronic and acute therapies. Cardiac and anti-diabetes brands registered growth of 18.7% and 15.8%, respectively. In acute therapies, gastroenterology grew at 1.3 times the market rate, while vitamins, minerals and nutrients (VMN) expanded at 1.4 times that rate.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8DIvUoX
via IFTTT

Read More

Lord’s Mark Industries Limited becomes Asia’s first company to secure multiple US FDA registrations for 200+ surgical and hygiene products; US exports to begin in December

Silvassa manufacturing expansion completed ahead of schedule as the company prepares to expand its international footprint across the United States and South America

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Z25eqPc
via IFTTT

Read More

Dr Reddy's bets on generic semaglutide, biosimilars

Dr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of generic semaglutide and the US launch of abatacept biosimilar are anticipated for future growth. The company aims to sell millions of pens for semaglutide with a focus on international markets. Furthermore, an expanding biosimilars portfolio aims to strengthen its position beyond traditional generics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3y6PozZ
via IFTTT

Read More

Rs 1 lakh to Rs 30,000: Cancer immunotherapy gets cheaper, but will patients get the price benefit?

Cheaper nivolumab biosimilars are expanding access to cancer immunotherapy in India, with one Mumbai oncologist reporting a more than 50% rise in prescriptions over six months. Prices have fallen from over Rs 1 lakh to around Rs 30,000 per cycle, but hospital stocking practices could determine whether patients benefit from lower costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RCM4mj0
via IFTTT

Read More

One Science Nutrition: Building a science-led approach to sports nutrition

One Science Nutrition was co-founded by Aman and Aniket Vachher to create credible sports nutrition products. The brand aims to cater to evolving consumer expectations around product quality and transparency. Their product range includes various supplements that support diverse fitness goals and health benefits. Future strategies involve leveraging artificial intelligence to enhance consumer experiences and product discovery. The founders emphasize maintaining core values while pursuing growth in the nutrition industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/90xr2IG
via IFTTT

Read More

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Johnson & Johnson reported results from an early-stage trial of their prostate cancer drug JNJ-6143. The trial involved patients with advanced prostate cancer who had undergone multiple treatments. Results showed 77% of patients experienced a significant drop in PSA levels after treatment. Additionally, 69% of patients demonstrated confirmed partial or complete tumor response through imaging. Common side effects included nausea and elevated cholesterol levels, with one patient discontinuing treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GY9MseC
via IFTTT

Read More

States urged to enforce ban on reuse of single-use medical devices

The Directorate General of Health Services has issued a directive to prohibit the reuse of single-use medical devices. Violations by some private hospitals have raised concerns regarding patient safety and regulatory compliance. The directive specifically targets misuse in high-stakes medical fields such as cardiology and neurosurgery. Monitoring and enforcement of compliance by healthcare establishments have been mandated.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dTYQWjS
via IFTTT

Read More

Jubilant Pharmova eyes $150 million through rupee debt sale, bankers say

Jubilant Pharmova plans to raise around Rs 14 billion ($150 million) through a three-year rupee bond offering to fund capital expenditure and refinance project-related liabilities at overseas subsidiaries. The proposed issuance, rated AA+ by India Ratings, could take place before the end of next month, according to two merchant bankers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5Ax9oDs
via IFTTT

Read More

From nasal delivery to sterile injectables: Biodeal Pharmaceuticals’ expansion plans

Biodeal Pharmaceuticals is set to broaden its horizons with a state-of-the-art sterile injectables plant in Himachal Pradesh. This venture will notably elevate its production capacities and diversify its contract development and manufacturing services. Biodeal is committed to fortifying existing partnerships with clients leveraging its innovative nasal and oral drug formulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3u5xN89
via IFTTT

Read More

Cipla subsidiary clears USFDA inspection with zero observations

Cipla on Friday said a routine US Food and Drug Administration (USFDA) inspection at its wholly owned subsidiary InvaGen Pharmaceuticals' manufacturing facility in Hauppauge, Long Island, New York.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BoM65tl
via IFTTT

Read More

At 22, he built a gym machine in his garage. Now, the man behind the ‘Ferrari of fitness’ is looking to India

Technogym founder Nerio Alessandri is looking to expand the Italian fitness and wellness company's presence in India, where fitness facility membership remains below 1% of the population. Founded in 1983, Technogym has grown from a garage startup into a global brand serving athletes, gyms, luxury hotels and households.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VH8bJRr
via IFTTT

Read More

Cancer drugs to get cheaper? Here’s what the latest government order says

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A7MUrnm
via IFTTT

Read More

From Continuous Data to Trusted Health Intelligence: What Abu Dhabi and India Can Learn From Each Other About Predictive Health?

Predictive health will depend not on how much data health systems collect, but on whether they can validate it, govern it responsibly, and translate it into earlier action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xsof6CR
via IFTTT

Read More

Sanofi healthcare receives CDSCO approval for Qftilia therapy for haemophilia patients in India

Sanofi Healthcare has obtained authorisation from the Central Drugs Standard Control Organisation for Qfitlia. This therapy is designed to prevent bleeding in haemophilia patients aged 12 years and older. Qfitlia offers unique protection for Haemophilia A and B patients, requiring only six injections annually. The approval follows promising results from the ATLAS phase 3 clinical trials. This advancement aims to enhance access to treatment options for patients in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XE29pxY
via IFTTT

Read More

Dr Reddy's gets DCGI nod for Zytorvi in advanced esophageal cancer

Dr Reddy's Laboratories has received approval for Zytorvi, an immunotherapy targeting advanced esophageal squamous cell carcinoma. This new indication allows treatment for adult patients with a combination of toripalimab, cisplatin, and paclitaxel. Approximately 80 percent of esophageal cancer cases in India are attributed to esophageal squamous cell carcinoma. The approval derives from positive results in the Phase 3 JUPITER-06 trial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/72My0Yt
via IFTTT

Read More

HealthRail: Turning India's hospital receivables into growth capital

In a strategic move to streamline hospital cash flow, HealthRail is offering expedited access to accrued revenues. This initiative specifically addresses the payment delays that hospitals experience with insurance providers and public funding programs. By lowering days sales outstanding for qualifying receivables, this system aims to substantially bolster hospitals' liquidity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LBOoExe
via IFTTT

Read More

NATCO Pharma subsidiary launches Carboplatin in US market to address shortages

Indian pharmaceutical company NATCO Pharma annouced the launch of Carboplatin Injection, a generic version of Paraplatin in the US market by its American subsidiary. The subsidiary would collaborate in manufacturing with Chennai-based Tero Labs Pvt Ltd. The launch is aimed at meeting the shortage of the drug. Carboplatin is directed towards the treatment of advanced ovarian carcinoma, including first-line combination therapy and palliative treatment of recurrent disease after prior chemotherapy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rDpavA1
via IFTTT

Read More

AIIMS doctors identify ‘Red Alert Zone’ to reduce risks in complex cancer surgery

AIIMS doctors have recognized two critical anatomical zones during complex cancer surgeries in women. These zones help reduce bleeding and prevent injuries to vital organs. One zone, known as 'Ray's Zone', is crucial for surgeries involving the pelvic area. The other, 'Ray's Hepatocaval Triangle', assists during liver mobilization near major vessels. Identifying these zones enhances surgical precision and patient outcomes in oncological procedures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MPDFt6b
via IFTTT

Read More

The burden of cancer drugs: Millions battle exorbitant prices as life-saving treatment slips out of reach

For millions of cancer patients, the cost of treatment can be as frightening as the diagnosis. From steep markups to patented drugs that remain out of reach, the affordability crisis runs deep. A proposed cap may help, but question remains if it will be enough to change the picture.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d2JXKVZ
via IFTTT

Read More

Aayush Wellness launches calcium, vitamin supplements; enters USD 16.3-bn bone & joint health segment

Aayush Wellness Limited has launched Aayush Calcium Vitamin Tablets, expanding its nutraceutical portfolio into the bone and joint health segment. The formulation combines calcium citrate, vitamin D2, magnesium, zinc and folic acid to support bone strength, calcium absorption and musculoskeletal health. The company said the launch aligns with growing consumer interest in preventive healthcare and nutritional supplements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vgTbfzQ
via IFTTT

Read More

NPPA caps trade margins on 137 cancer drugs at 30%, revised prices from Nov 9

India's National Pharmaceutical Pricing Authority has capped trade margins for 137 anti-cancer drugs at 30% of their maximum retail price. This cap, effective from November 9, applies to all listed drugs, including Atezolizumab and Bevacizumab. Manufacturers must adjust prices if they exceed the newly calculated maximum retail price. Compliance will be monitored by state drug controllers and hospitals, which play a significant role in drug supply.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5ABuEGc
via IFTTT

Read More

Shridevi Institute, US-based Vaxonyx sign MoU for AI-driven cancer and genomic research

Shridevi Institute of Medical Sciences in Tumakuru has signed an MoU with Vaxonyx LLC for collaboration. This partnership aims to focus on AI-enabled bioinformatics and genomic research tailored for Indian populations. They will develop personalized cancer therapies by analyzing individual tumor profiles. The collaboration will also explore the creation of genomic datasets to improve genetic models. Moreover, they intend to develop DNA-based vaccine candidates for relevant public health issues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nj7thfi
via IFTTT

Read More

NITI Aayog explores policies to boost India's medical and dental device manufacturing industry

NITI Aayog is exploring policy measures to improve the manufacturing capabilities of medical and dental devices in India. The meeting included domestic manufacturers, government officials, and experts from IIT Delhi and IIT Mumbai. Key challenges such as regulatory hurdles and cost disadvantages faced by Indian manufacturers were discussed extensively. The industry body AiMeD emphasized the need for simpler regulations and financial support for local manufacturers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OU16ieb
via IFTTT

Read More

HLL Lifecare launches eStore to expand direct-to-consumer reach

State-owned company HLL Lifecare launched HLL eStore, a digital platform aimed to expand access to its healthcare and wellness products across the country. The platform would be part of its broader digital transformation strategy, enabling customers, business partners and healthcare institutions to engage with the company through an integrated online marketplace. The eStore also offers medical products and supplies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XZRSFnY
via IFTTT

Read More

AYUSH sees rise in patents filings showcasing innovation growth; 4,077 applications filed from 2014 to 2026

Ayush-related Intellectual Property activity has seen substantial growth, with over 4,000 patent applications from 2014 to 2026. The Ministry of Ayush emphasises the increasing participation of individuals and institutions in this sector. Patent filings peaked post-COVID, reflecting a focus on research and innovation. Natural persons and educational institutions contributed significantly to the total filings and grants. The government continues to foster an enabling environment for traditional knowledge and scientific research.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lxD4gmf
via IFTTT

Read More

India needs 2.6 billion sq ft of healthcare space by 2035, says CBRE

India requires an expansion of its healthcare infrastructure with an additional 2.6 billion sq ft by 2035. This need arises due to an expected demand for nearly 2.9 million more hospital beds nationwide. Current statistics show India has only 1.6 hospital beds per 1,000 people, significantly less than the global average. Certain states face much lower hospital bed density compared to their disease burden, indicating unmet healthcare needs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rfzT6tg
via IFTTT

Read More

Indian, German firms to collaborate on immunoglobulin products: Indian Embassy

Germany's Neovii Biotech and India's VINS Bioproducts will explore collaboration on manufacturing and commercialising immunoglobulin products, including anti-thymocyte globulin used in organ transplantation and certain blood disorders. Facilitated by the Indian Embassy in Berlin, the agreement involves technology transfer to India and could strengthen domestic capabilities in specialised biological products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VT6fGIw
via IFTTT

Read More

Biocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launch

Biocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to launch Pebrilzo in early 2027 in the UK and EU, and in late 2028 in the US. In response to Genentech's patent infringement suit, the New Jersey court dismissed the case at Genentech's request. The details of the settlement agreement remain confidential between the companies involved.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NhPxSjv
via IFTTT

Read More

Novo Holdings, GIC, Axight look to back AIG Hospitals; Founders aim to pare 10-12% stake at Rs 24,000 cr valuation

Novo Holdings and GIC are discussing investing Rs 2,000-2,500 crore in AIG Hospitals based in Hyderabad. The investment reflects a growing interest among private equity firms in Indian healthcare. Founders of AIG Hospitals, Duvvur Nageshwar Reddy and Penmetsa Venkata Subbaraju, are planning a stake sale. AIG Hospitals has plans for a new facility in Visakhapatnam and aims to grow significantly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/e4M9VTd
via IFTTT

Read More

Health ministry asked to examine coronary stent safety concerns

Cabinet secretariat has directed the Union health ministry to investigate safety issues related to coronary stents. These concerns were raised by Rajya Sabha member Ajeet Madhavrao Gopchade regarding models withdrawn in Sri Lanka. Gopchade emphasized the need for strengthening India's regulatory framework for coronary stents. He called for improved clinical documentation and robust traceability for implanted stents. His representation highlighted the importance of patient follow-up and monitoring of device-related complications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/k5eM81q
via IFTTT

Read More

Biocon clears path for cancer drug launch

Biocon has finalized a global settlement and license agreement with Genentech for its drug Pebrilzo. This agreement addresses all ongoing legal disputes between the two companies in jurisdictions such as the US and Canada. Under the terms, Biocon can launch Pebrilzo in the EU and UK by early 2027 and in the US by Q3 of 2028. Other global launches are planned between 2026 and 2028, depending on regulatory approvals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3YycUMS
via IFTTT

Read More

NMC Healthcare founder BR Shetty files $15 billion lawsuit against Bank of Baroda

The suit, filed in the Bombay High Court, seeks $5 billion in direct damages for alleged fraud and negligence, $5 billion in consequential damages and $5 billion in compensation for reputational harm arising from various actions taken by the bank, including a lookout circular issued against him.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5WdTHKj
via IFTTT

Read More

Biocon founder Kiran Mazumdar Shaw says India must shift pharma industry from generics to innovation-led growth

Kiran Mazumdar-Shaw emphasized the importance of building an innovation-driven pharmaceutical industry in India. She highlighted the need for continued investment in research and regulatory reforms to enhance drug development. The industry must focus on maintaining high-quality standards as it seeks to innovate. Closer cooperation between industry and regulators can help sustain momentum during this transition. India has the potential to participate actively in the global innovation ecosystem.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0UTfv9L
via IFTTT

Read More

Zydus moves closer to US market for Keytruda biosimilar as FDA accepts application

Zydus Lifesciences has received acceptance for its application regarding the biosimilar of Keytruda, which is a major cancer drug. The USFDA is expected to complete its review process by the third quarter of 2027. This biosimilar, named FYB206, was developed without a comparative Phase III efficacy trial. Zydus aims to make effective treatments more accessible in the oncology field in North America.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dk6iDnb
via IFTTT

Read More

Panel to finalise cancer drugs for 30% trade margin cap; Rs 2,500 crore annual savings possible

An expert group is finalizing the list of cancer medicines for a new trade margin cap. The government plans to implement a 30% cap to reduce drug prices and save patients money. Retail prices of some anti-cancer drugs could drop by up to 70% as a result of this cap. The trade margin rationalisation will apply to all cancer medicines, including branded and generic versions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WohERwL
via IFTTT

Read More

Supreme Court questions govt over drug pricing, asks why cap limited to anti-cancer medicines

The Supreme Court expressed its worry over the government's restriction of price control measures to only anti-cancer drugs, questioning why other vital medications lack similar oversight when sold at exorbitant rates. The Solicitor General emphasized the importance of maintaining a balance between drug availability and market dynamics in determining prices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Luz1p5H
via IFTTT

Read More

Joint pain isn’t the same for everyone. Should treatment be?

Joint pain is frequently dismissed as an inevitable consequence of aging; however, it may point to significant underlying issues. Symptoms like stiffness and inflammation warrant a consultation with healthcare professionals. Various forms of arthritis necessitate unique treatment approaches, and symptoms can differ from person to person. Maintaining an active lifestyle and a healthy weight is crucial for preserving joint health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KfBZET3
via IFTTT

Read More

Roche calls for global healthcare overhaul to tackle disease burden

Roche highlights the urgent need for a transformation in global healthcare to effectively tackle chronic diseases. Jorg Rupp pointed out that existing healthcare infrastructures are largely reactive, falling short in proactively addressing the rise of non-communicable diseases. This burgeoning issue not only challenges health systems but also imposes heavy financial demands. Governments must begin viewing healthcare as a crucial investment aimed at enhancing health outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BQphSg0
via IFTTT

Read More

Tricog Health targets 100 million cardiac screenings by 2030: CEO Dr Charit Bhograj

Bengaluru-based Tricog Health aims to conduct 100 million cardiac screenings by 2030, having screened over 41 million patients since its founding in 2014. The healthtech firm uses AI-enabled ECG devices and specialist reviews to detect heart conditions, with operations across several Indian states and 14 countries. Its technology aims to reduce diagnosis delays and improve early detection of cardiovascular diseases.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fBrLahj
via IFTTT

Read More

Indian pharma's risk aversion holding back innovation: Kiran Mazumdar-Shaw

Biocon chairperson Kiran Mazumdar-Shaw calls for greater use of digital technology to speed up drug development, as industry leaders push for a shift beyond generics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1Sm9YKA
via IFTTT

Read More

Health ministry proposes curbs on prescription drug ads by retailers, wholesalers and distributors

The union health ministry has proposed extending advertising restrictions on prescription drugs to retailers and distributors. This change will bar them from advertising certain medicines without prior government approval. The amendment affects drugs covered under Schedules H, H1, and X, which require medical oversight. The existing regulations already apply to pharmaceutical manufacturers. The recommendation for this amendment comes from the Drugs Technical Advisory Board.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FKdI3EX
via IFTTT

Read More

Experiments on animals set to become easier

The Centre plans to significantly change the regulations governing animal experimentation. The proposed rules aim to allow institutional ethics panels to approve most experiments. Currently, only small animal experiments can be approved at the institutional level while larger ones require central oversight.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AKjUpnS
via IFTTT

Read More

Hair fall decoded: Causes, triggers, and warning signs

For many, hair shedding can raise concerns, with various elements at play like stress, hormonal imbalances, and nutrition. Recognizing the difference between shedding and breakage is essential, as each has distinct roots and remedies. Noting specific loss patterns can guide you towards effective treatments. Additionally, seeking expert guidance can shed light on potential health issues impacting your hair's condition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/L1l56pJ
via IFTTT

Read More

National Medical Commission bans doctors & hospitals from using AI-generated patient testimonials, fake cure claims in medical ads

The National Medical Commission has implemented new ethical advertising guidelines affecting doctors and hospitals. These guidelines prohibit the use of artificial intelligence for generating promotional content or testimonials. Measures have also been taken to restrict paid patient solicitation and misleading claims in advertisements. Strict penalties have been established for non-compliance, including warnings and license suspensions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GCsa0t7
via IFTTT

Read More

Govt set to cap trade margins on more cancer drugs before SC hearing

The Indian government plans to announce a new list of cancer drugs for trade margin rationalisation today. Union Health Minister JP Nadda will make the announcement just ahead of a Supreme Court hearing on October 12. This decision comes after concerns regarding the price gap between retailer prices and MRP of some cancer medications. Trade margins were capped previously, leading to significant price reductions on several anti-cancer drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WawMSEi
via IFTTT

Read More

Supreme Court seeks committee to curb pharma firms’ unethical marketing practices

The Supreme Court has directed the government to form a committee regarding pharmaceutical marketing regulations. This follows concerns over unethical practices influencing doctors’ prescribing decisions and patient health outcomes. Petitioners are advocating for stronger legal frameworks beyond the current voluntary code. They emphasize the need for a statutory code supported by penalties to protect the right to health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OuafslW
via IFTTT

Read More

Ayush services sector supports 1.76 million livelihoods; women constitute 43% of the workforce

The Ayush services sector supports 1.76 million livelihoods in India and has a significant female workforce. Women's participation in organized segments, including hospitals, exceeds 50 percent in several areas. The sector has the potential to expand substantially, generating an estimated USD 216-318 billion by 2047. Ayurveda remains the largest individual system of revenue generation within the sector, contributing significantly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8vEpzIN
via IFTTT

Read More

The 30-Minute Medicine Problem

How India's largest ePharmacy is building an in-house quick-commerce engine across cities and why moving medicines in under an hour is far more complicated than it looks

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c4NTo3D
via IFTTT

Read More

Drug panel rejects child images on cough syrup labels, proposes age warning for use below 4 years

Cough syrup bottles will soon include a prominent red warning stating their use is not recommended for children under four. An expert committee rejected child-oriented imagery on labels, which could imply suitability for young children. This decision follows ongoing concerns about the safety of cough syrups in pediatric care. The proposed change aims to prevent confusion regarding age restrictions for these medications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BwgnLQy
via IFTTT

Read More

Lord’s Mark strengthens UK and UK allied market strategy with regulatory backing for IVD portfolio.

In an exciting development, Lord's Mark Industries has secured registration for its In-Vitro Diagnostic portfolio with the MHRA, significantly boosting market access. This follows the approval of their AI-enhanced Renalyx haemodialysis system in the UK. The firm aims for a December 2026 market launch for its IVD products, ahead of schedule, along with a planned January 2027 start for its pathology lab, highlighting its strong commitment to global healthcare integration.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hoce1DA
via IFTTT

Read More

Centre may seek legal view on licensing of sterile drugs

The government is actively exploring a proposal to expand central licensing authority over all sterile drug products following a recent Supreme Court decision that restricted the enforcement authority of central officials. A meeting of the drugs consultative committee underscored the essential requirement for specialized regulatory oversight for these sensitive products, aiming for uniform regulations. A dedicated sub-committee will evaluate the proposal's feasibility and gather legal insights before any definitive actions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p6l2iYZ
via IFTTT

Read More

Ayush services sector supports 1.76 million livelihoods; women constitute 43% of the workforce

The Ayush services sector supports 1.76 million livelihoods in India and has a significant female workforce. Women's participation in organized segments, including hospitals, exceeds 50 percent in several areas. The sector has the potential to expand substantially, generating an estimated USD 216-318 billion by 2047. Ayurveda remains the largest individual system of revenue generation within the sector, contributing significantly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zRjr0f8
via IFTTT

Read More

Wall Street’s $10 billion India hospital bet sparks a fight over bills

Wall Street has poured about $10 billion into Indian hospital chains over the past five years, with investors including Blackstone, KKR, TPG and General Atlantic betting on India’s huge shortage of hospital beds and rising demand for specialised care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W2kVamB
via IFTTT

Read More

Robotic surgery gains rapid ground in India, Delhi NCR leads: Experts

India is rapidly scaling up robotic surgery, with procedures rising from 8,912 in 2021 to 44,857 in 2025, while Delhi NCR has emerged as the country’s biggest hub with 39 hospitals using robotic systems. Experts say the next phase could include wider use of telesurgery, remote mentoring and access to specialist care beyond major cities, subject to regulatory and cybersecurity safeguards.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EZDxXmd
via IFTTT

Read More

Maharashtra FDA cancels Cipla's Pune warehouse licences over Reactin Plus packaging claims

Maharashtra's Food and Drug Administration has cancelled Cipla Pharma's distribution licenses due to serious violations. The FDA discovered irregularities with Reactin Plus Tablets, including misbranding and unsafe storage practices. Following inspections, it was revealed that expired medicines were stored incorrectly without proper documentation. The licensing authority’s decision was based on findings from earlier proceedings and legal directions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lwzvNLP
via IFTTT

Read More

India has biotech talent and know-how, but funding ecosystem lags: Lilly CEO

Eli Lilly intends to innovate in the weight-loss market, launching up to four new products in the coming years. The success of Mounjaro and Zepbound significantly boosted the company's sales and market value. Eli Lilly sees potential in India's biotech sector, despite challenges in the research funding environment. The company is open to partnerships with Indian biotechnology firms for future collaborations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/v7L6naV
via IFTTT

Read More

‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEO

Eli Lilly has experienced significant growth, reaching a market capitalization over $1 trillion. The company aims to maintain its leadership in anti-obesity drugs through ongoing innovation and development. With successful trials for drugs like retatrutide and Foundayo, Lilly is expanding its product offerings. The company recognizes the importance of India as a growing market for healthcare investments and partnerships.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/s7BoJzj
via IFTTT

Read More

Karnataka flags 52x mark-up on cancer drugs, seeks Centre's intervention

Karnataka conducted inspections revealing significant price disparities between hospital procurement and patient billing for cancer drugs and medical devices. The state government has urged the Centre to implement transparency in pricing and regulate trade margins for essential medicines. Mark-ups observed ranged from 10 to over 52 times the actual procurement costs for various items.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xKPHXfq
via IFTTT

Read More

Rasayan Labs launches AI-native drug discovery platform at ICT Mumbai

In an exciting development, Rasayan Labs has unveiled a groundbreaking AI-based platform to enhance computational chemistry and drug discovery initiatives. This innovative platform merges critical functions, including retrosynthesis and ADMET prediction, to optimize research efficiency. Free access will be granted to researchers at the Institute of Chemical Technology, marking a pivotal collaboration that seeks to dramatically reduce drug development timelines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KhXkoyt
via IFTTT

Read More